NASDAQ:BTTX Better Therapeutics Q2 2023 Earnings Results & Report $0.0001 0.00 (0.00%) As of 11/3/2026 09:46 AM Eastern Better Therapeutics beat analyst earnings expectations in its Q2 2023 results, released August 9, 2023. The company reported EPS of -$0.24 versus the -$0.39 consensus estimate. Research:Profile Earnings Announcement Details QuarterQ2 2023Report DateAugust 9, 2023 Better Therapeutics EPS ResultsActual EPS-$0.24Consensus EPS -$0.39Beat/MissBeat by +$0.15One Year Ago EPSN/AEPS Beat Rate4 of last 6 quartersBetter Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsBetter Therapeutics' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Better Therapeutics Q2 2023 Earnings FAQ Did Better Therapeutics beat earnings estimates for Q2 2023? Better Therapeutics (NASDAQ:BTTX) reported earnings of -$0.24 per share for Q2 2023, beating the consensus estimate of -$0.39. The report was announced on Wednesday, August 9, 2023. When is Better Therapeutics' next earnings date? Better Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Better Therapeutics on the company's earnings history page. Better Therapeutics Earnings HeadlinesBetter Therapeutics consensus price target lowered by 71.43% to $1.53November 3 at 5:24 AM | msn.comBTTX Better Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. | Weiss Ratings (Ad)Janux Therapeutics Inc (JANX) Receives a Buy from BTIGNovember 7, 2024 | markets.businessinsider.comThis High-Flying Stock Just Became a Better BuyOctober 31, 2024 | fool.comBicara Therapeutics: A Buy Rating on Promising Clinical Progress and Financial FortitudeOctober 9, 2024 | markets.businessinsider.comSee More Better Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Better Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Better Therapeutics and other key companies, straight to your email. Email Address About Better TherapeuticsBetter Therapeutics (NASDAQ:BTTX) was a digital therapeutics company focused on developing prescription software designed to address chronic metabolic and cardiometabolic conditions. Its approach combined behavioral therapy, personalized digital coaching and clinical content delivered through software intended for use alongside standard medical care. The company’s lead product, AspyreRx, formerly known as BT-001, was authorized by the U.S. Food and Drug Administration in 2023 as a prescription digital therapeutic for adults with type 2 diabetes. The software was designed to support behavior change and help patients manage their condition in conjunction with traditional treatment. Better Therapeutics was based in the United States and primarily targeted the U.S. healthcare market. Following the FDA authorization of AspyreRx, the company announced a strategic review and subsequently reported a wind-down of operations. Information about its current commercial activities and leadership is limited.View Better Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it SimpleEnergy Transfer's Earnings Miss May Be Hiding Its Strongest Advantage Upcoming Earnings Enbridge (11/6/2026)Brookfield Asset Management (11/6/2026)Humana (11/6/2026)Moderna (11/6/2026)Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
